Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 1,352

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia

Open access
Yankova, Eliza, Blackaby, Wesley, Albertella, Mark, Rak, Justyna, De Braekeleer, Etienne, Tsagkogeorga, Georgia, Pilka, Ewa S., Aspris, Demetrios, Leggate, Dan, Hendrick, Alan G., Webster, Natalie A., Andrews, Byron, Fosbeary, Richard, Guest, Patrick, Irigoyen, Nerea, Eleftheriou, Maria, Gozdecka, Malgorzata, Dias, Joao M. L., Bannister, Andrew J., Vick, Binje, Jeremias, Irmela, Vassiliou, George S., Rausch, Oliver, Tzelepis, Konstantinos, Kouzarides, Tony·2021·Nature

Abstract

N6-methyladenosine (m6A) is an abundant internal RNA modification1,2 that is catalysed predominantly by the METTL3–METTL14 methyltransferase complex3,4. The m6A methyltransferase METTL3 has been linked to the initiation and maintenance of acute myeloid leukaemia (AML), but the potential of therapeutic applications targeting this enzyme remains unknown5–7. Here we present the identification and characterization of STM2457, a highly potent and selective first-in-class catalytic inhibitor of METTL3, and a crystal structure of STM2457 in complex with METTL3–METTL14. Treatment of tumours with STM2457 leads to reduced AML growth and an increase in differentiation and apoptosis. These cellular effects are accompanied by selective reduction of m6A levels on known leukaemogenic mRNAs and a decrease in their expression consistent with a translational defect. We demonstrate that pharmacological inhibition of METTL3 in vivo leads to impaired engraftment and prolonged survival in various mouse models of AML, specifically targeting key stem cell subpopulations of AML. Collectively, these results reveal the inhibition of METTL3 as a potential therapeutic strategy against AML, and provide proof of concept that the targeting of RNA-modifying enzymes represents a promising avenue for anticancer therapy. Treatment with a specific inhibitor of the N6-methyladenosine methyltransferase METTL3 leads to reduced growth of cancer cells, indicating the potential of approaches targeting RNA-modifying enzymes for anticancer therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-021-03536-w

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 1,352

Metadata

Authors
Yankova, E., Blackaby, W., Albertella, M., Rak, J., De Braekeleer, E., Tsagkogeorga, G., Pilka, E. S., Aspris, D., Leggate, D., Hendrick, A. G., Webster, N. A., Andrews, B., Fosbeary, R., Guest, P., Irigoyen, N., Eleftheriou, M., Gozdecka, M., Dias, J. M. L., Bannister, A. J., Vick, B., Jeremias, I., Vassiliou, G. S., Rausch, O., Tzelepis, K., & Kouzarides, T.
Venue
Nature
Published
2021-04-26
Volume
593
Issue
7860
Pages
597-601
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W3159494124
Cited by
1,352
References
10
FWCI
55.35
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. https://app.cochat.ai/papers/10.1038/s41586-021-03536-w
The paper
Yankova, E., Blackaby, W., Albertella, M., Rak, J., De Braekeleer, E., Tsagkogeorga, G., Pilka, E. S., Aspris, D., Leggate, D., Hendrick, A. G., Webster, N. A., Andrews, B., Fosbeary, R., Guest, P., Irigoyen, N., Eleftheriou, M., Gozdecka, M., Dias, J. M. L., Bannister, A. J., . . . Kouzarides, T. (2021). Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature. https://doi.org/10.1038/s41586-021-03536-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.